1. © 2012 Health Level Seven ® International. All Rights Reserved. HL7 and Health Level Seven are registered trademarks of Health Level Seven International. Reg. U.S. TM Office. Allergy and Intolerances Project HL7 WG Meeting 2013 Cambridge Patient Care WG September 25, 2013 Q4

2. © 2012 Health Level Seven ® International. All Rights Reserved. HL7 and Health Level Seven are registered trademarks of Health Level Seven International. Reg. U.S. TM Office. Agenda Update on Domain Analysis Model Update on Clinical Statement DSTU Clinical Statement ballot reconciliation Planning for conference calls 01/01/2011 2

3. © 2012 Health Level Seven ® International. All Rights Reserved. HL7 and Health Level Seven are registered trademarks of Health Level Seven International. Reg. U.S. TM Office. Domain Analysis Model Balloted in January and May 2013 Ballot for Informative currently open until October 7 th ! Use cases:  Observed new allergy  New reported intolerance  Allergic reaction to a device  Misattribution of an allergy  Known allergy is resolved  Unable to determine triggering agent  No known history of allergy or intolerances  Allergy and intolerance information not asked  Patient documents allergy in a PHR  Reconciliation of allergy/intolerance list 01/01/2011 3

4. © 2012 Health Level Seven ® International. All Rights Reserved. HL7 and Health Level Seven are registered trademarks of Health Level Seven International. Reg. U.S. TM Office. Allergy and Intolerance Information Model 01/01/2011 4

5. © 2012 Health Level Seven ® International. All Rights Reserved. HL7 and Health Level Seven are registered trademarks of Health Level Seven International. Reg. U.S. TM Office. DAM – Outstanding Issues Ballot reconciliation Publishing of DAM as informative Preferences - next steps required? FHIR resource – any outstanding issues? Cross-walk with other projects? 01/01/2011 5

6. © 2012 Health Level Seven ® International. All Rights Reserved. HL7 and Health Level Seven are registered trademarks of Health Level Seven International. Reg. U.S. TM Office. Phase Two – Clinical Models Just completed DSTU ballot cycle  29 ballot comments Allergy vs. intolerance Criticality vs. severity 01/01/2011 6

7. © 2012 Health Level Seven ® International. All Rights Reserved. HL7 and Health Level Seven are registered trademarks of Health Level Seven International. Reg. U.S. TM Office. Conference Calls Next steps  Testing models – need additional testers  Existing - adverse reaction content in V3?  Reconciliation  Terminology requirements NDFRT – PharmacyHIT Other substances – resources available? Va/NHS/SNOMED/RxNorm  Templates for C-CDA for allergy list and adverse reaction  Preferences – through OO – ballot in January OO has the allergy use cases as well as diet order use cases Harmonize with care plan preference component PC WG will need to provide tx preferences, end-of-life, advanced directives 01/01/2011 7

8. © 2012 Health Level Seven ® International. All Rights Reserved. HL7 and Health Level Seven are registered trademarks of Health Level Seven International. Reg. U.S. TM Office. Ballot reconciliation 01/01/2011 8

9. © 2012 Health Level Seven ® International. All Rights Reserved. HL7 and Health Level Seven are registered trademarks of Health Level Seven International. Reg. U.S. TM Office. 01/01/2011 9